British Journal of Cancer

Article	Citations
Advancing radiomics from contrast-enhanced mammography in breast cancer	219
The EXO1/Polη/Polι axis as a promising target for miR-3163-mediated attenuation of cancer stem-like cells in non-small cell lung carcinoma	169
Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer	151
Hepatitis B virus X protein promotes MAN1B1 expression by enhancing stability of GRP78 via TRIM25 to facilitate hepatocarcinogenesis	142
Years of life lost due to cancer in the United Kingdom from 1988 to 2017	142
Proactive breast cancer risk assessment in primary care: a review based on the principles of screening	140
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)	133
Correction: YY1 targets tubulin polymerisation-promoting protein to inhibit migration, invasion and angiogenesis in pancreatic cancer via p38/MAPK and PI3K/AKT pathways	129
Correction: Wnt/ERK/CDK4/6 activation in the partial EMT state coordinates mammary cancer stemness with self-renewal and inhibition of differentiation	128
Breast cancer risk prediction with a modified BOADICEA model in Danish women	119
Extranodal extension in lung adenocarcinoma: pathological insights and its implication as a histological marker of clinical aggressiveness	116
Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study	111
Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells	109
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer	106
Investigation of the gut microbiome, bile acid composition and host immunoinflammatory response in a model of azoxymethane-induced colon cancer at discrete timepoints	101
Neoplasm risk in individuals with neurofibromatosis 1 – a Danish nationwide cohort study with long-term follow-up	101
Extruded small extracellular vesicles: splinters of circulating tumour cells may promote cancer metastasis?	98
Diagnostic accuracy of combinatorial mRNA biomarkers for non-invasive detection and therapy monitoring of oral and oropharyngeal SCC	93
Assessments of social vulnerability on laryngeal cancer treatment & prognosis in the US	91
Fibroblast activation protein-targeted near-infrared photoimmunotherapy depletes immunosuppressive cancer-associated fibroblasts and remodels local tumor immunity	90
Integrated genomic and transcriptomic analysis reveals the activation of PI3K signaling pathway in HPV-independent cervical cancers	90
DRP1 inhibition-mediated mitochondrial elongation abolishes cancer stemness, enhances glutaminolysis, and drives ferroptosis in oral squamous cell carcinoma	88
Correction To: Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial	84
A very-hot food and beverage thermal exposure index and esophageal cancer risk in Malawi and Tanzania: findings from the ESCCAPE case–control studies	83
Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis	83

Hit it hard: qualitative patient perspectives on the optimisation of immune checkpoint inhibition	83
Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer	82
Navigating therapeutic strategies: HPV classification in head and neck cancer	81
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)	81
Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours	79
Comprehensive assessment of actionable genomic alterations in primary colorectal carcinoma using targeted next-generation sequencing	77
Identifying health conditions associated with an increased risk of pancreatic ductal adenocarcinoma at medium term in nationwide electronic health records of primary care physicians	77
Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value	74
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate	74
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer	73
Genomic ALK alterations in primary and relapsed neuroblastoma	72
Metabolic adaptations in prostate cancer	70
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer	69
Targeting mitochondrial oxidative phosphorylation: lessons, advantages, and opportunities	69
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analy	68
Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer	67
Surveillance after childhood cancer: are survivors with an increased risk for cardiomyopathy regularly followed-up?	67
Metastasis-associated fibroblasts in peritoneal surface malignancies	67
Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker	65
Abemaciclib plus fulvestrant in treating hormone-receptor positive, HER2-negative advanced breast cancer—comparing real-world outcomes in England to the MONARCH-2 trial	64
Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma	61
Somatic hits in mismatch repair genes in colorectal cancer among non-seminoma testicular cancer survivors	61
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer	60
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors	59
Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification	58
A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer	58
Deep learning analysis of histopathological images predicts immunotherapy prognosis and reveals tumour microenvironment features in non-small cell lung cancer	58
Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in England	55
Serum 25-hydroxyvitamin D concentrations and colorectal cancer incidence in adults with type 2 diabetes	55
Long-term trends in incidence, characteristics and prognosis of screen-detected and interval cancers in women participating in the Dutch breast cancer screening programme	54
Albendazole inhibits colon cancer progression and therapy resistance by targeting ubiquitin ligase RNF20	53
Nutritional status, body composition and chemotherapy dosing in children and young people with cancer: a systematic review by the SIOP nutrition network	53
Identification of increased dedifferentiation along the Prom1+ cancer cells in Müllerian adenosarcoma with sarcomatous overgrowth	53
Multistate models for the natural history of cancer progression	52
Progress and priorities in reducing the time to cancer diagnosis	52
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination	52
PTBP1 drives c-Myc-dependent gastric cancer progression and stemness	51
SLC7A11-AS1 contributes to prolonged activation of activin A/Smad signaling by suppressing PPM1A myristoylation in pancreatic cancer	51
Emerging nanomedical strategies for direct targeting of pediatric and adult diffuse gliomas	51
Relation knowledge distillation 3D-ResNet-based deep learning for breast cancer molecular subtypes prediction on ultrasound videos: a multicenter study	51
Introduction and impact of routine whole genome sequencing in the diagnosis and management of sarcoma	50
Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis	50
Long-term use of antihypertensive medications, hypertension and colorectal cancer risk and mortality: a prospective cohort study	49
Contralateral breast cancer after radiotherapy and hormone therapy in two cohorts of US breast cancer survivors	49
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)	48
Effect of risk-based screening for upper gastrointestinal cancers: a multi-center real-world study	48
Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC	47
Hypoxia- and Postirradiation reoxygenation-induced HMHA1/ARHGAP45 expression contributes to cancer cell invasion in a HIF-dependent manner	47
Implications of obesity and insulin resistance for the treatment of oestrogen receptor-positive breast cancer	46
The SRC-family serves as a therapeutic target in triple negative breast cancer with acquired resistance to chemotherapy	45

EEF1A2 promotes HIF1A mediated breast cancer angiogenesis in normoxia and participates in a positive feedback loop with HIF1A in hypoxia	45
Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial	45
Adolescent dietary patterns in relation to later prostate cancer risk and mortality in the NIH-AARP Diet and Health Study	45
Risk of subsequent primary oral cancer in a cohort of 69,460 5-year survivors of childhood and adolescent cancer in Europe: the PanCareSurFup study	44
eIF3i facilitates NELFCD translation to promote metastasis via regulating EMT and invadopodia	44
Optimizing adjuvant treatment strategies for non-pancreatic periampullary cancers	44
Editorial Expression of Concern: Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-	44
Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II st	43
Clinical outcome and prognostic factors for Asian patients in Phase I clinical trials	43
Retraction Note: Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis	42
Distant recurrence and margin involvement in invasive breast cancer	42
The impact of the first 2 years of the COVID-19 pandemic on breast cancer diagnoses: a population-based study in England	42
The Glasgow Microenvironment Score and risk and site of recurrence in TNM I–III colorectal cancer	42
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer	42
Tissue factor in cancer-associated thromboembolism: possible mechanisms and clinical applications	41
Mass spectrometric insights into the protein composition of human cutaneous neurofibromas: comparison of neurofibromas with the overlying skin	41
Cancer in Costello syndrome: a systematic review and meta-analysis	41
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer	41
The prognostic impact of peritoneal tumour DNA in gastrointestinal and gynaecological malignancies: a systematic review	41
Chromatin accessibility uncovers KRAS-driven FOSL2 promoting pancreatic ductal adenocarcinoma progression through up-regulation of CCL28	40
Immune checkpoint inhibitor combinations—current and emerging strategies	40
Efficacy and quality of life for FOLFOX/bevacizumab +/− irinotecan in first-line metastatic colorectal cancer—final results of the AIO CHARTA trial	40
Urinary proteome and metabolome uncover tumor microenvironment and cellular metabolism changes of renal clear cell carcinoma	40
Molecular response assessment using circulating tumor DNA (ctDNA) in advanced solid tumors	40
A metabolomic analysis of adiposity measures and pre- and postmenopausal breast cancer risk in the Nurses’ Health Studies	39
Capturing breast cancers’ copy-number landscape in routine pathology: Exploiting low-resolution, genome-wide sequencing to identify HRD and beyond	39
What do women think about having received their breast cancer risk as part of a risk-stratified NHS Breast Screening Programme? A qualitative study	39
Manassantin A inhibits tumour growth under hypoxia through the activation of chaperone-mediated autophagy by modulating Hsp90 activity	38
High-throughput precision MRI assessment with integrated stack-ensemble deep learning can enhance the preoperative prediction of prostate cancer Gleason grade	38
Cancer risk in individuals with polydactyly: a Swedish population-based cohort study	38
Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets	38
MET exon 14 skipping mutation drives cancer progression and recurrence via activation of SMAD2 signalling	38
The prognostic value of MEK pathway–associated estrogen receptor signaling activity for female cancers	38
Correction: Modelled mortality benefits of multi-cancer early detection screening in England	37
Routes to diagnosis for hepatocellular carcinoma patients: predictors and associations with treatment and mortality	37
Correction: Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption	37
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer	37
Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway	37
Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases	37
Clinical efficacy and immune response of neoadjuvant camrelizumab plus chemotherapy in resectable locally advanced oesophageal squamous cell carcinoma: a phase 2 trial	37
Thinking inside the box: intracellular roles for complement system proteins come into focus	36
Correction to: Methyl-CpG-binding domain 3 inhibits epithelial–mesenchymal transition in pancreatic cancer cells via TGF-β/Smad signalling	36
A UK prospective multicentre decision impact, decision conflict and economic evaluation of the 21-gene assay in women with node+ve, hormone receptor+ve, HER2-ve breast cancer	35
Cannabinoids induce cell death in leukaemic cells through Parthanatos and PARP-related metabolic disruptions	35
Deciphering the central role of TMOD2 in colorectal cancer progression and metastasis	35
Benchmarking standard-of-care and emerging genomic approaches to enhance diagnosis in pediatric acute lymphoblastic leukemia	35
Immune evasion in lung metastasis of leiomyosarcoma: upregulation of EPCAM inhibits CD8+ T cell infiltration	35
Cost-effectiveness of one-off upper abdominal CT screening as an add-on to lung cancer screening in England	34
Sequential targeting of PARP with carboplatin inhibits primary tumour growth and distant metastasis in triple-negative breast cancer	34
Investigating PAK inhibition in combination with PD-1 blockade to enhance cytotoxic CD8+ T cell-mediated killing and suppress invasion of ovarian cancer cells	34
Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study	34
Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia	34
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours	34
Modelled impact of a multi-cancer early detection screening programme on cancer treatment in England	33
Population-based nasopharyngeal carcinoma survival in southern China	33
Transcriptomic and functional analyses reveal a tumour-promoting role for the IL-36 receptor in colon cancer and crosstalk between IL-36 signalling and the IL-17/ IL-23 axis	33
Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions	33
The in vitro dynamics of pseudo-vascular network formation	33
Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis in pancreatic cancer	32
A multimodal imaging study to highlight elastin-derived peptide pro-tumoral effect in a pancreatic xenograft model	32
Confidence bands in survival analysis	32
Correction: Differential cellular origins of the extracellular matrix of tumor and normal tissues according to colorectal cancer subtypes	32
Novel prognostic implications of complement activation in the tumour microenvironment for de novo metastatic BRAF V600E mutant colorectal cancer	32
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer	32
Oesophageal cancer awareness and anticipated time to help-seeking: results from a population-based survey	32
50 years on and still very much alive: ‘Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics’	31
Breast cancer cell-derived adrenomedullin confers cancer-associated adipose remodeling through the cAMP/Creb1/Zeb1 axis	31
Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients	31
Reply to Dr. Rafael Rosell: Shedding some light on the unresolved issue of YAP1 Ser397 phosphorylation in cancer	31
UK Biobank: a globally important resource for cancer research	31
Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients	31
Identification of diagnostic biomarkers in prostate cancer-related fatigue by construction of predictive models and experimental validation	31
Sodium nitrite orchestrates macrophage mimicry of tongue squamous carcinoma cells to drive lymphatic metastasis	30
Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk	30
Correction: Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility	30
Stroma AReactive Invasion Front Areas (SARIFA) and the tumour immune microenvironment in colorectal cancer	30
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial	30
Correction to: The Cancer Research UK Stratified Medicine Programme as a model for delivering personalised cancer care	30
The role of genetic predisposition in cardiovascular risk after cancer diagnosis: a matched cohort study of the UK Biobank	30
Regulatory non-coding somatic mutations as drivers of neuroblastoma	29

Transient centrosome loss in cultured prostate epithelial cells induces chromosomal instability to produce an oncogenic genotype that correlates with poor clinical outcomes	29
Targeting the DNA damage response prevents regrowth of colorectal peritoneal metastasis-derived organoids following treatment with mitomycin C	29
Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status	29
Sorafenib plus selective internal radiotherapy with 90Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial	29
Health benefits and harms of mammography screening in older women (75+ years)—a systematic review	29
Nonrandomised controlled trial in recurrent glioblastoma patients: the promise of autologous tumour lysate-loaded dendritic cell vaccination	29
EIF4A3-negatively driven circular RNA β-catenin (circβ-catenin) promotes colorectal cancer progression via miR-197-3p/CTNND1 regulatory axis	28
Galectin-9-driven immunosuppressive macrophage population shapes the lymph node metastatic microenvironment	28
Effects of preoperative recombinant Interleukin 2-based immunomodulation on outcome after gastrointestinal cancer surgery: a systematic review and meta-analysis	28
Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-γ-induced tumour-associated fibroblasts remodelling	28
Survival outcomes of ERBB2-amplified metastatic colorectal cancer treated with first-line chemotherapy	28
Reasons for non-feasibility of therapeutic drug monitoring of oral targeted therapies in oncology – an analysis of the closed cohorts of a multicentre prospective study	28
Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer	28
Boron neutron capture therapy (BNCT) for experimental bladder cancer: systemic or intravesical approach	28
Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer	28
Preferences for multi-cancer tests (MCTs) in primary care: discrete choice experiments of general practitioners and the general public in England	28
Identification of a distinct cluster of LY6E+ macrophages in esophageal squamous cell carcinoma: functional phenotype, spatial interaction, and prognostic significance	28
DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance	28
HECTD3 regulates the tumourigenesis of glioblastoma by polyubiquitinating PARP1 and activating EGFR signalling pathway	27
Economic evaluation of artificial intelligence for cancer detection in the UK breast screening programme	27
Impact of the selective A2AR and A2BR dual antagonist AB928/etrumadenant on CAR T cell function	27
Repositioning canakinumab for non-small cell lung cancer—important lessons for drug repurposing in oncology	27
Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancer	27
Blocking mitochondrial leucine transamination enhances T-cell activation and improves T-cell immunity against OVA-producing EL4 lymphoma	27
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations	27
Targeting oncogenic microRNAs from the miR-371~373 and miR-302/367 clusters in malignant germ cell tumours causes growth inhibition through cell cycle disruption	27
Postdiagnosis physical activity is associated with improved survival in prostate cancer patients treated with surgery but not with radiation therapy	27
Patient-centered outcomes according to cancer status in cardiac surgery patients: a population-based cohort study	27
Plasma extracellular vesicle circRNA signature and resistance to abiraterone in metastatic castration-resistant prostate cancer	27
Exosomal transfer of miR-181b-5p confers senescence-mediated doxorubicin resistance via modulating BCLAF1 in breast cancer	27
COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer	26
The National COVID Cancer Antibody Survey: a hyper-accelerated study proof of principle for cancer research	26
Correction: DKC1 enhances angiogenesis by promoting HIF-1α transcription and facilitates metastasis in colorectal cancer	26
Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma	26
Cancer-associated fibroblasts expressing fibroblast activation protein and podoplanin in non-small cell lung cancer predict poor clinical outcome	26
Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer	26
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma	26
Response to: Genetic risk scores may compound rather than solve the issue of prostate cancer overdiagnosis (BJC-LT3342090)	26
The long noncoding RNA lncZBTB10 facilitates AR function via S-palmitoylation to promote prostate cancer progression and abiraterone resistance	25
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology	25
Hypoxia-inducible factor 3α1 increases epithelial-to-mesenchymal transition and iron uptake to drive colorectal cancer liver metastasis	25
Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records	25
The Rac1-USP11 feedback amplification loop: a radiation-activated engine driving radioresistance in hepatocellular carcinoma	25
Anti-angiogenic therapy using the multi-tyrosine kinase inhibitor Regorafenib enhances tumor progression in a transgenic mouse model of ß-cell carcinogenesis	25
Associations between serum glucose, insulin, insulin resistance and the risk of incident primary liver cancer or chronic liver disease mortality: a nested case–control study	25
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?	25
Functional footprints of homologous recombination deficiency in prostate cancer revealed by ctDNA fragmentation and transcription factor accessibility	25
AKT/mTOR as a targetable hub to overcome multimodal resistance to EGFR inhibitors in oesophageal squamous cell carcinoma	25
Tumour-based epigenetic signatures as markers of prostate cancer aggressiveness after radical prostatectomy	25
A digital quality measure for emergency presentation of pancreatic cancer	24
A study of subjective memory impairment in long-term testicular cancer survivors	24
Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study	24
Pre-diagnostic circulating untargeted metabolomics and risk of overall and clinically significant prostate cancer: a systematic review and meta-analysis	24
Role of 18F-FDG-PET/CT in the initial staging of very high-risk Ewing Sarcoma in a prospective multicentric Phase II Study: Is there still a place for bone marrow sampling?	24
Artificial intelligence-driven microRNA signature for early detection of gastric cancer: discovery and clinical functional exploration	24
Mutation of the proline P81 into a serine modifies the tumour suppressor function of the von Hippel–Lindau gene in the ccRCC	24
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1)	24
Modelled mortality benefits of multi-cancer early detection screening in England	24
A combination of intrinsic and extrinsic features improves prognostic prediction in malignant pleural mesothelioma	24
Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients	24
ctDNA variations according to treatment intensity in first-line metastatic colorectal cancer	24
Understanding genetic architecture of breast cancer: how can proteome-wide association studies contribute?	24
Editorial Expression of Concern: Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential	24
Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer	24
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2	24
Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition	23
Attention-based deep learning for breast lesions classification on contrast enhanced spectral mammography: a multicentre study	23
UDP-glucose ceramide glucosyltransferase promotes radioresistance via membrane reorganization to maintain redox balance in glioblastoma	23
Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis	23
Intratumour heterogeneity, from hypothesis to the clinic	23
Prognostic value of post-operative iron biomarkers in colorectal cancer: population-based patient cohort	23
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies	23
Silencing of NUP62 overcomes osimertinib resistance via ubiquitination of survivin in non-small cell lung cancer cells	23
Epithelial−mesenchymal transition induced by tumor cell-intrinsic PD-L1 signaling predicts a poor response to immune checkpoint inhibitors in PD-L1-high lung cancer	23
Genome-wide polygenic risk scores for colorectal cancer have implications for risk-based screening	23
Comparison of methods for cancer stem cell detection in prognosis of early stages NSCLC	23
Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer	23
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells	23
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy	23
Comment on: “Neoadjuvant chemotherapy is noninferior to chemoradiotherapy for early-onset locally advanced rectal cancer in the FOWARC trial”	23
Breast density is strongly associated with multiparametric magnetic resonance imaging biomarkers and pro-tumorigenic proteins in situ	22
Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus	22
Chemotherapy-induced neuropathy in monomethyl Auristatin E treatment: prevention by lithium	22
Retraction Note: CDK5RAP3 as tumour suppressor negatively regulates self-renewal and invasion and is regulated by ERK1/2 signalling in human gastric cancer	22
HeLa cells cross-contaminated nasopharyngeal carcinoma cell lines: Still a common problem	22
Editorial Expression of Concern: Upregulation of p27 and its inhibition of CDK2/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21	22
Birthweight, height, and body mass index in relation to the expression of stem cell markers among women with benign breast biopsies in the Nurses’ Health Study II	22
LHX2 facilitates the progression of nasopharyngeal carcinoma via activation of the FGF1/FGFR axis	22
PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours	22
Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer	22
Correction: TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory	22
Evolving roles of CD38 metabolism in solid tumour microenvironment	22
Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study	22
Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer	21
Correction: E2F7−EZH2 axis regulates PTEN/AKT/mTOR signalling and glioblastoma progression	21